“The vaccine activates many antibodies”. Steps forward thanks to the tests on elderly people
The vaccine candidate developed by the University of Oxford in collaboration with IRBM of Pomezia (Rome), and produced by AstraZeneca, «has triggered a robust immune response in elderly people, the group at highest risk», as revealed by the Financial Times. It’s definitely good news. Piero Di Lorenzo, President of IRBM, announces with optimism that «if phase III of the clinical trial is concluded by December without adverse events, the first 2-3 million doses of the vaccine will arrive in Italy by year end».
Article by Grazia Longo published on La Stampa – 27/10/2020